Changes in Serum Aryl Hydrocarbon Receptor Concentrations Following Tuberculosis Preventive Therapy in Adults with Type 2 Diabetes
Year: 2026
Type: article
Study design: Observational Study
Abstract: Latent tuberculosis infection (LTBI) is prevalent among patients with type 2 diabetes, and aryl hydrocarbon receptor (AhR) has been reported to be associated with LTBI. This observational study aimed to determine whether serum AhR levels decrease after tuberculosis prevention therapy (TPT). Patients with type 2 diabetes were enrolled for LTBI screening, and serum AhR levels were measured for those with a positive QuantiFERON-TB result. The patients received TPT, according to clinical practice: either weekly rifapentine plus isoniazid for 3 months (3HP) or daily isoniazid for 9 months (9H). Serum AhR levels were measured during a follow-up assessment at 36 weeks after enrollment in the patients who underwent continuous TPT for >3 months. Among 88 patients who completed the follow-up assessment, 47 (53.4%) received the 3HP regimen, and 41 (46.6%) received the 9H regimen. Serum AhR levels significantly decreased after TPT in the 3HP (45.4 [24.8, 55.44] to 13.4 [6.4, 23.8] pg/mL, p < 0.001) and 9H groups (43.4 [27.2, 60.8] to 14.6 [7.3, 21.3] pg/mL, p < 0.001). However, there was no statistically significant difference in the reduction in serum AhR levels between the 3HP and 9H groups (p = 0.286). In conclusion, serum AhR levels significantly decreased following TPT with the 3HP or 9H regimens.
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,499
Awards: G2087531560, G6425349703
OpenAlex ID: W7226004668
